- Home
- SERA vs KYTX Comparison
SERA vs KYTX Comparison
Compare SERA & KYTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SERA
- KYTX
- Stock Information
- Founded
- SERA 2008
- KYTX 2018
- Country
- SERA United States
- KYTX United States
- Employees
- SERA N/A
- KYTX N/A
- Industry
- SERA Precision Instruments
- KYTX
- Sector
- SERA Health Care
- KYTX
- Exchange
- SERA Nasdaq
- KYTX NYSE
- Market Cap
- SERA 142.9M
- KYTX 125.2M
- IPO Year
- SERA 2021
- KYTX 2024
- Fundamental
- Price
- SERA $3.68
- KYTX $1.93
- Analyst Decision
- SERA
- KYTX Buy
- Analyst Count
- SERA 0
- KYTX 4
- Target Price
- SERA N/A
- KYTX $19.00
- AVG Volume (30 Days)
- SERA 105.6K
- KYTX 294.1K
- Earning Date
- SERA 03-19-2025
- KYTX 03-27-2025
- Dividend Yield
- SERA N/A
- KYTX N/A
- EPS Growth
- SERA N/A
- KYTX N/A
- EPS
- SERA N/A
- KYTX N/A
- Revenue
- SERA $77,000.00
- KYTX N/A
- Revenue This Year
- SERA $4,536.36
- KYTX N/A
- Revenue Next Year
- SERA $411.43
- KYTX N/A
- P/E Ratio
- SERA N/A
- KYTX N/A
- Revenue Growth
- SERA N/A
- KYTX N/A
- 52 Week Low
- SERA $3.33
- KYTX $1.90
- 52 Week High
- SERA $12.36
- KYTX $25.84
- Technical
- Relative Strength Index (RSI)
- SERA 37.12
- KYTX 27.74
- Support Level
- SERA $3.77
- KYTX $2.20
- Resistance Level
- SERA $4.20
- KYTX $2.57
- Average True Range (ATR)
- SERA 0.24
- KYTX 0.19
- MACD
- SERA 0.01
- KYTX -0.02
- Stochastic Oscillator
- SERA 34.83
- KYTX 4.00
About SERA Sera Prognostics Inc.
Sera Prognostics Inc is a health diagnostic company. It develops diagnostic tests for the early prediction of a woman's individualized risk of premature birth, preeclampsia, gestational diabetes, stillbirth, and other conditions. The proprietary proteomics and bioinformatics platform of the company helps to improve maternal and neonatal health by discovering, developing, and commercializing blood-based biomarker tests, and predictive analytic products and services.
About KYTX KYVERNA THERAPEUTICS INC
Kyverna Therapeutics Inc is a clinical-stage biopharmaceutical company. It is focused on developing cell therapies for patients suffering from autoimmune diseases. Its product KYV-101, is an autologous CD19 CAR T-cell product candidate made from an underlying chimeric antigen receptor, or CAR. It is also developing KYV-201, an allogeneic therapy containing the same CAR as KYV-101, to develop it in multiple autoimmune diseases.